About and sources
marked.bio maps cancer biomarkers to the clinical trials, approved therapies and companies built around them. It is a free tool for founders, scientists and investors.
Where the data comes from
- Clinical trials
- Every interventional cancer trial on ClinicalTrials.gov, downloaded through its public API. Last downloaded 2026-10-27. ClinicalTrials.gov is run by the US National Library of Medicine; we do not edit its records.
- Approvals
- FDA approvals from FDA labels and announcements, and EU approvals from European Medicines Agency product pages (EPARs). Curated by hand, one row per approved indication, each with its source. Rows not yet checked against the official label are marked "To verify".
- Biomarker definitions
- Our own curation, informed by CIViC (CC0).
How trials are matched
Trials don't have a biomarker field, so we read their titles, conditions and eligibility criteria. A trial is shown for a biomarker when a plain, positive mention appears in its title or inclusion criteria. Mentions that are negated ("EGFR wild-type"), excluded, only allowed ("patients with ALK fusion are also eligible") or only about prior treatment are left out.
A broad match means the trial asks for a wider group that contains the biomarker, such as "sensitizing EGFR mutation" on the EGFR exon 19 deletion page.
We measure the matcher against hand-labelled trials. It finds nearly all relevant trials, but on fresh samples only about six in ten shown matches actually required the biomarker; the rest only mentioned it. We keep tightening the rules with each labelled round. That's why every trial shows the words that matched: you can check it in a few seconds.
Companies
Companies are the lead sponsors of active, industry-sponsored trials, with subsidiaries merged into their parent where we know of the link (for example Genentech into Roche). Collaborators and academic sponsors are not counted.
Limitations
- Registry records can be out of date. Trials marked "Status may be outdated" say they are active but haven't been updated in over two years.
- Approvals cover the FDA and the EMA only, not national or other regulators.
- A drug marked FDA or EU in a trial is approved for this biomarker in at least one indication, not necessarily in that trial's setting.
Disclaimer
For research and informational purposes only. Nothing on this site is medical advice or investment advice. Patients should talk to their doctor about trials and treatment.